{"text": ["Roche", "(RHHBY)", "Presents", "Encouraging", "Data", "on", "SMA", "Drug", "Risdiplam"], "created_at": "2018-10-04 22:51:13"}
{"text": ["Roche", "(RHHBY)", "Presents", "Encouraging", "Data", "on", "SMA", "Drug", "Risdiplam"], "created_at": "2018-10-04 22:51:13"}
{"text": ["Novartis", "ADR\u2019s", "Performance", "and", "Revenue", "Estimates", "for", "Q3", "2018"], "created_at": "2018-10-04 13:01:57"}
{"text": ["GlaxoSmithKline", "ADR\u2019s", "Performance", "and", "Revenues", "in", "Q3", "2018"], "created_at": "2018-10-04 11:32:36"}
{"text": ["Moody's:", "Biosimilars", "a", "growing", "challenge", "biotech", "drugs,", "with", "European", "market", "developing", "more", "quickly", "than", "the", "US"], "created_at": "2018-10-04 07:20:06"}
